Spots Global Cancer Trial Database for toripalimab
Every month we try and update this database with for toripalimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | NCT06139211 | Advanced Solid ... | JS015 Toripalimab Paclitaxel Irinotecan Capecitabine Oxaliplatin Bevacizumab Fluorouracil Leucovorin Gemcitabine Albumin-Bound P... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma | NCT04713761 | Malignant Pleur... | Toripalimab | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | NCT04627363 | Hepatocellular ... Bevacizumab Liver Neoplasms Toripalimab Oxaliplatin | Hepatic arteria... Bevacizumab Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 | NCT06028672 | Gestational Tro... | Toripalimab Actinomycin-D | 18 Years - 60 Years | Peking Union Medical College Hospital | |
| Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma | NCT04248387 | Melanoma Stage ... | Toripalimab | 18 Years - | Fudan University | |
| Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer | NCT06362317 | Biliary Tract N... | Toripalimab Lenvatinib Gemox Chemother... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | NCT03919383 | Hepatocellular ... | Lenvatinib Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | NCT04376866 | Recurrent Nasop... | Toripalimab | 18 Years - 65 Years | Cancer Hospital of Guangxi Medical University | |
| Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial | NCT06256237 | Limited Stage S... | JS004 Toripalimab surgery Etoposide Platinum | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China | |
| Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | NCT05803915 | Oral Squamous C... | Toripalimab | 18 Years - | Peking Union Medical College Hospital | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | NCT05056337 | Hepatocellular ... | Lenvatinib 4 MG... Toripalimab TACE | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | NCT05031494 | Melanoma Pancreatic Duct... | YH003 Toripalimab Nab-paclitaxel Gemcitabine | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | NCT05539118 | Melanoma | Recombinant hum... Toripalimab Anlotinib hydro... | 18 Years - 75 Years | Xijing Hospital | |
| Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma | NCT04443036 | Gastric Carcino... | Albumin-Bound P... Toripalimab | 18 Years - 70 Years | China Medical University, China | |
| Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | NCT04778956 | Nasopharyngeal ... PD-1 Surgery | Toripalimab salvage surgery | 18 Years - 70 Years | Sun Yat-sen University | |
| Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | NCT04169672 | Advanced Solid ... | Surufatinib Toripalimab | 18 Years - 75 Years | Hutchmed | |
| A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | NCT04914286 | Advanced Solid ... | GFH018 Toripalimab | 18 Years - 75 Years | Genfleet Therapeutics (Shanghai) Inc. | |
| Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma | NCT04926532 | Hepatocellular ... | Toripalimab Sorafenib | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer | NCT04553939 | Urothelial Carc... Bladder Cancer | Toripalimab Gemcitabine | 18 Years - 75 Years | Henan Cancer Hospital | |
| The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer | NCT05798845 | NSCLC | SBRT+LDRT Toripalimab Chemotherapy dr... Toripalimab | 18 Years - 75 Years | Shanghai Chest Hospital | |
| A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | NCT04640545 | Advanced Melano... | LBL-007 Toripalimab Axitinib Tablet... | 18 Years - | Nanjing Leads Biolabs Co.,Ltd | |
| Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) | NCT04807140 | Head and Neck S... | Toripalimab, na... Toripalimab Surgical resect... | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma | NCT04716751 | Tracheal Squamo... | Toripalimab | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Toripalimab Combined With SBRT for NSCLC | NCT06293690 | Non-small Lung ... | Toripalimab Toripalimab | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT05861557 | Locally Advance... | Toripalimab Stereotactic Bo... | 18 Years - | Tianjin Medical University General Hospital | |
| Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer | NCT06039631 | Larynx Cancer Hypopharyngeal ... | Surgery Radiation Toripalimab | 18 Years - 75 Years | Fudan University | |
| The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001 | NCT03301688 | NSCLC | Toripalimab | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT | NCT05628922 | Nasopharyngeal ... | Toripalimab Induction chemo... | 18 Years - 70 Years | Fudan University | |
| JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | NCT05664971 | Advanced Lung C... | Recombinant hum... Toripalimab Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Etoposide | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | NCT06079112 | Advanced Urothe... | 9MW2821 Toripalimab | 18 Years - 80 Years | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status | NCT05669092 | Toripalimab Radiation | Toripalimab CRT SCRT XELIRI FOLFRINOX | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer | NCT04718701 | Pancreatic Neop... Metastatic Panc... Locally Advance... | Anlotinib+Torip... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | NCT04973904 | Cervical Cancer | Toripalimab Paclitaxel Cisplatin Bevacizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | NCT06389526 | Advanced or Met... | CHS-1000 Toripalimab | 18 Years - | Coherus Biosciences, Inc. | |
| A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | NCT05386888 | NSCLC, Stage II... | GFH018 Toripalimab Paclitaxel Carboplatin Cisplatin Pemetrexed Thoracic Radiat... GFH018 | 18 Years - | Genfleet Therapeutics (Shanghai) Inc. | |
| HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | NCT05493332 | Hepatocellular ... | HAIC(FOLFOX) Oxaliplatin Leucovorin Fluorouracil Toripalimab Donafenib | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | NCT04653480 | Colorectal Canc... | Surufatinib Toripalimab chemotherapy | 18 Years - 75 Years | Zhejiang University | |
| Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC | NCT06081582 | Squamous Cell C... | Toripalimab | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | NCT05147844 | Nasopharyngeal ... | Toripalimab | 18 Years - 75 Years | Xinqiao Hospital of Chongqing | |
| Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | NCT05970627 | Adenocarcinoma ... Adenocarcinoma ... Epstein-Barr Vi... | Toripalimab Oxaliplatin S1 | 18 Years - 80 Years | First Affiliated Hospital of Zhejiang University | |
| Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer | NCT04437212 | Advanced Esopha... | Toripalimab | 18 Years - 75 Years | RenJi Hospital | |
| Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | NCT05021328 | NSCLC | Toripalimab Anlotinib SBRT 7Gy✖️5 QD | 18 Years - | Hubei Cancer Hospital | |
| Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE) | NCT04278222 | Gastric Cancer Gastro-oesophag... Immunotherapy Anlotinib Toripalimab | Anlotinib Plus ... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | NCT06387628 | TNBC - Triple-N... | LM-108 Toripalimab Eribulin Nab paclitaxel | 18 Years - 75 Years | Fudan University | |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | NCT04709380 | Radiotherapy Toripalimab Sorafenib Advanced Hepato... | Radiotherapy pl... Sorafenib | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | NCT05615974 | Malignant Tumor... | LM101 Toripalimab Rituximab Envafolimab | 18 Years - | LaNova Medicines Limited | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy | NCT04418648 | Small Cell Lung... | Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer | NCT06093438 | Cervical Cancer Induction Chemo... Immunotherapy | Toripalimab | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | NCT04229849 | Esophageal Squa... | Anrotenib plus ... Toripalimab | 18 Years - | Henan Cancer Hospital | |
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies | NCT05253105 | Previously Trea... Malignancies | TAB006 Toripalimab | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | NCT06065813 | Non-small Cell ... Neoadjuvant The... Radiotherapy Immunotherapy | Toripalimab Conventional se... opreation | 18 Years - 70 Years | Northern Jiangsu People's Hospital | |
| Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | NCT04177797 | Esophageal Squa... | Toripalimab | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) | NCT06187597 | Locally Advance... | S-1 Toripalimab Intensity-modul... | 70 Years - 85 Years | Sun Yat-sen University | |
| Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients | NCT04418154 | Triple Negative... | epirubicin hydr... Cyclophosphamid... Albumin bound p... Toripalimab | 18 Years - 70 Years | Fudan University | |
| A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | NCT05031494 | Melanoma Pancreatic Duct... | YH003 Toripalimab Nab-paclitaxel Gemcitabine | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | NCT06065813 | Non-small Cell ... Neoadjuvant The... Radiotherapy Immunotherapy | Toripalimab Conventional se... opreation | 18 Years - 70 Years | Northern Jiangsu People's Hospital | |
| A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers | NCT04603040 | Recurrent or Me... | Toripalimab | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC | NCT05888402 | Local Advanced ... | Toripalimab Concurrent chem... | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | NCT04238169 | Non-Small-Cell ... | Bevacizumab Toripalimab SBRT | 18 Years - 70 Years | Xinqiao Hospital of Chongqing | |
| Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification | NCT04880811 | Esophageal Squa... | Afatinib Toripalimab | 18 Years - 70 Years | Peking University | |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | NCT06333561 | Hepatocellular ... Lenvatinib PD-1 Inhibitor Hepatic Arteria... | Hepatic arteria... Lenvatinib Tislelizumab Toripalimab Sintilimab Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma | NCT05240404 | Hepatocellular ... | Toripalimab Thermal ablatio... | 18 Years - 75 Years | Xiangya Hospital of Central South University | |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | NCT04709380 | Radiotherapy Toripalimab Sorafenib Advanced Hepato... | Radiotherapy pl... Sorafenib | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | NCT05955105 | Head and Neck C... Cervical Cancer Endometrial Can... Triple Negative... Ovarian Cancer Soft Tissue Sar... Melanoma Nasopharyngeal ... Non Small Cell ... Classic Hodgkin... | ILB-2109 Toripalimab | 18 Years - 80 Years | Innolake Biopharm | |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma | NCT03946943 | Soft Tissue Sar... Undifferentiate... | Anlotinib Toripalimab Blood Draw Tumor Specimen ... | 16 Years - | The First Hospital of Jilin University | |
| Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma | NCT05420597 | Laryngeal Cance... Hypopharyngeal ... | Toripalimab | 18 Years - 75 Years | Fudan University | |
| Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | NCT05798533 | Solid Tumor | Neo-T Toripalimab Tislelizumab | 18 Years - 75 Years | BGI, China | |
| Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | NCT05996484 | Esophageal Carc... Neoadjuvant The... | Toripalimab Anlotinib hydro... Albumin paclita... Cisplatin | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | NCT06080854 | Pancreatic Carc... | Toripalimab Gemcitabine Nab paclitaxel SBRT | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors | NCT06038396 | Advanced Solid ... | RC118 Toripalimab | 18 Years - 75 Years | RemeGen Co., Ltd. | |
| Toripalimab Combined With SBRT for NSCLC | NCT06293690 | Non-small Lung ... | Toripalimab Toripalimab | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study | NCT04462965 | Mucosal Melanom... | Toripalimab Temozolomide | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer | NCT04718701 | Pancreatic Neop... Metastatic Panc... Locally Advance... | Anlotinib+Torip... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers | NCT04211168 | Advanced Biliar... | Toripalimab plu... | 18 Years - | Peking Union Medical College Hospital | |
| Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer | NCT04304248 | Non Small Cell ... | Albumin-bound p... | 18 Years - 80 Years | Sun Yat-sen University | |
| Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | NCT05539118 | Melanoma | Recombinant hum... Toripalimab Anlotinib hydro... | 18 Years - 75 Years | Xijing Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
